Table 5. Association of confirmed UBC susceptibility variants with overall mortality among MIBC patients.
| Unadjusted (N = 273) | Adjusteda (N = 273) | |||||
| SNP/CNV | Genotype | N (n events) | HR (95% CI) | P trend | HR (95% CI) | P trend |
| rs9642880 | TT | 63 (18) | Ref. | 0.69 | Ref. | 0.56 |
| GT | 139 (39) | 0.94 (0.54–1.64) | 0.86 (0.49–1.50) | |||
| GG | 70 (23) | 1.12 (0.61–2.08) | 1.18 (0.64–2.18) | |||
| rs710521 | AA | 152 (50) | Ref. | 0.16 | Ref. | 0.12 |
| AG | 101 (27) | 0.77 (0.48–1.23) | 0.88 (0.55–1.41) | |||
| GG | 20 (4) | 0.59 (0.21–1.63) | 0.52 (0.19–1.45) | |||
| rs2294008b | CC | 79 (18) | Ref. | 0.22 | Ref. | 0.25 |
| CT | 133 (43) | 1.45 (0.84–2.52) | 1.22 (0.70–2.13) | |||
| TT | 61 (20) | 1.48 (0.78–2.79) | 1.45 (0.77–2.74) | |||
| rs798766 | CC | 178 (49) | Ref. | 0.21 | Ref. | 0.28 |
| CT | 85 (27) | 1.13 (0.71–1.80) | 1.03 (0.65–1.65) | |||
| TT | 10 (5) | 2.14 (0.85–5.37) | 2.41 (0.96–6.05) | |||
| rs401681 | CC | 100 (24) | Ref. | 0.13 | Ref. | 0.29 |
| CT | 114 (36) | 1.29 (0.77–2.17) | 1.23 (0.73–2.06) | |||
| TT | 59 (21) | 1.56 (0.87–2.79) | 1.39 (0.76–2.45) | |||
| rs2736098 | GG | 99 (31) | Ref. | 0.10 | Ref. | 0.35 |
| AG | 80 (15) | 0.54 (0.29–0.99) | 0.64 (0.34–1.19) | |||
| AA | 18 (4) | 0.68 (0.24–1.93) | 0.95 (0.33–2.72) | |||
| rs11892031c | AA | 243 (69) | Ref. | 0.20 | Ref. | 0.20 |
| AC | 30 (12) | 1.50 (0.81–2.76) | 1.49 (0.81–2.75) | |||
| CC | 0 (0) | NA | NA | |||
| rs8102137 | TT | 107 (34) | Ref. | 0.49 | Ref. | 0.57 |
| CT | 130 (38) | 0.92 (0.58–1.45) | 0.93 (0.59–1.48) | |||
| CC | 36 (9) | 0.77 (0.37–1.61) | 0.81 (0.39–1.69) | |||
| rs1014971 | AA | 123 (34) | Ref. | 0.97 | Ref. | 0.92 |
| AG | 124 (41) | 1.20 (0.76–1.89) | 1.05 (0.66–1.66) | |||
| GG | 26 (6) | 0.79 (0.33–1.89) | 0.87 (0.37–2.08) | |||
| rs1058396 | GG | 78 (28) | Ref. | 0.29 | Ref. | 0.45 |
| AG | 137 (37) | 0.73 (0.44–1.19) | 0.69 (0.42–1.13) | |||
| AA | 58 (16) | 0.75 (0.41–1.39) | 0.85 (0.46–1.57) | |||
| rs1495741d | GG/AG | 92 (32) | Ref. | 0.17 | Ref. | 0.09 |
| AA | 181 (49) | 0.73 (0.47–1.14) | 0.68 (0.43–1.06) | |||
| GSTM1 deletion | +/+ and +/− | 104 (23) | Ref. | 0.03 | Ref. | 0.09 |
| −/− | 146 (51) | 1.70 (1.04–2.79) | 1.53 (0.93–2.51) | |||
CNV: copy number variant; HR: hazard ratio; CI: confidence interval;
a
with adjustment for extended/metastasized (i.e., primary stage T4(b) ór any T with N+/N≥1 and/or M1) vs. localized disease (i.e., primary stage T2-T4a with N0/NX and M0/MX) in multivariable Cox proportional hazard regression analyses;
b
P for trend (unadjusted) for independent rs2978974 SNP at the 8q24.3 locus is 0.16;
c
P for trend (unadjusted) for causal risk variant (rs17863783) at the 2q37.1 locus is 0.92;
d
rs1495741: tag SNP for NAT2 acetylation status (GG = rapid, AG = intermediate, AA = slow)